« Back to Medicines list

Cilique 250/ 35 microgram tablets

  • Name:

    Cilique 250/ 35 microgram tablets

  • Company:
    info
  • Active Ingredients:

    Ethinylestradiol, Norgestimate

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 09/01/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 16/10/2019

Click on this link to Download PDF directly

Consilient Health Ltd

Consilient Health Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name altavitaD3 1,000 IU soft capsules Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name altavitaD3 25,000 IU oral solution Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name altavitaD3 25,000 IU soft capsules Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name altavitaD3 50,000 IU soft capsules Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name altavitaD3 7,000 IU soft capsules Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name Azalia 75 microgram film-coated tablets Active Ingredients Desogestrel
Medicine Name Cadelius 600 mg / 1,000 IU orodispersible tablets Active Ingredients Calcium Carbonate, Colecalciferol (Vitamin D3)
Medicine Name Cilique 250/ 35 microgram tablets Active Ingredients Ethinylestradiol, Norgestimate
Medicine Name Elvina 0.03mg/3mg Film-coated Tablets Active Ingredients Drospirenone, Ethinylestradiol
Medicine Name Elvinette 0.02mg/3mg film-coated tablets Active Ingredients Drospirenone, Ethinylestradiol
Medicine Name Mysimba 8 mg/90 mg prolonged-release tablets Active Ingredients Bupropion Hydrochloride, Naltrexone Hydrochloride
Medicine Name Ovreena 30 micrograms/150 micrograms coated tablets Active Ingredients Ethinylestradiol, Levonorgestrel
Medicine Name Violite 100/20 micrograms film-coated tablets Active Ingredients Ethinylestradiol, Levonorgestrel
1 - 0 of 13 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 9 January 2020 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Free text change information supplied by the pharmaceutical company

To include the following contraindication in section 2.1 of our package leaflet: ‘If you have cancer affected by sex hormones – such as some cancers of the breast or womb lining’

Updated on 16 October 2019

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose

Free text change information supplied by the pharmaceutical company

Update of the product information in line with the reference product.

Updated on 16 October 2019 PIL

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect

Free text change information supplied by the pharmaceutical company

Update of the product information in line with the reference product.

Updated on 11 March 2019 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to date of revision

Updated on 11 March 2019

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Updated on 1 October 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 1 October 2018

Reasons for updating

  • New SmPC for new product